Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Wegovy (semaglutide) is an FDA-approved prescription medication designed for chronic weight management
Retatrutide is the unimolecular triple agonist furthest in development and data from phase 2 trials suggests that this may soon become the most potent weight-lowering pharmacotherapy to be licenced
These effects contribute to weight loss that varies by agent and dosetypically ranging from 5-8% with liraglutide 3 mg (Saxenda), up to 15% with semaglutide 2.4 mg (Wegovy), and potentially up to 20% with higher doses of tirzepatide (Zepbound)
Some patients experience some form of gastrointestinal discomfort while taking semaglutide
Some of these approaches, despite not currently being listed in the summary of product characteristics, can effectively mitigate the occurrence and severity of adverse effects, notably enhancing patients adherence to treatment and persistence
When the patient's condition involves more than a structural problem, the options run out fast
US$ 25.89
US$ 25.98
US$ 25.90
US$ 21.65
US$ 23.85
US$ 28.78
